文献速递瓣膜病与结构性心脏病

18F-氟化钠PET-CT检测与预测生物主动脉瓣退变

Detection and Prediction of Bioprosthetic Aortic Valve Degeneration.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

研究通过离体退化生物瓣及两个临床队列(含71例无已知功能障碍患者),评估18F-氟化钠PET-CT对生物主动脉瓣退变的检测与预测价值。结果显示PET摄取与组织退变共定位,且能预测瓣膜功能快速恶化及新发功能障碍,是多变量分析中唯一独立预测因子。

要点

  • 18F-氟化钠PET摄取与离体退化生物瓣组织学退变共定位。
  • 无已知功能障碍患者中PET摄取者瓣膜功能年化恶化更快。
  • 基线PET摄取是未来生物瓣功能障碍的唯一独立预测因子。

核心结论

  • 18F-氟化钠PET-CT可识别亚临床生物主动脉瓣退变,并强效预测后续瓣膜功能障碍。

研究设计与样本

  • 离体退化生物瓣行组织学与PET对照检查。
  • 两个队列(伴或不伴生物瓣功能障碍)行CT血管造影、18F-氟化钠PET及2年系列超声随访。
  • 71例无已知生物瓣功能障碍患者纳入分析。

主要发现

  • 所有离体退化生物瓣均显示18F-氟化钠PET摄取并与组织学退变共定位。
  • 71例中14例CT见异常瓣叶病理,24例有PET摄取(靶本比1.55,IQR 1.44–1.88)。
  • PET摄取增高者峰值跨瓣流速年化变化0.30(IQR 0.13–0.61) vs. 0.01(IQR -0.05–0.16) ms⁻¹/年,p<0.001。
  • PET摄取与所有常规超声瓣膜功能指标恶化相关(如峰值流速变化r=0.72,p<0.001)。
  • 随访新发明显生物瓣功能障碍的10例基线均有PET摄取(靶本比1.89,IQR 1.46–2.59),多变量分析中PET摄取为唯一独立预测因子。

临床怎么用

  • 对生物主动脉瓣患者可考虑18F-氟化钠PET-CT识别亚临床退变高危者。
  • PET摄取阳性者应加强超声随访监测瓣膜功能恶化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bioprosthetic aortic valve degeneration is increasingly common, often unheralded, and can have catastrophic consequences. OBJECTIVES: The authors sought to assess whether 18F-fluoride positron emission tomography (PET)-computed tomography (CT) can detect bioprosthetic aortic valve degeneration and predict valve dysfunction. METHODS: Explanted degenerate bioprosthetic valves were examined ex vivo. Patients with bioprosthetic aortic valves were recruited into 2 cohorts with and without prosthetic valve dysfunction and underwent in vivo contrast-enhanced CT angiography, 18F-fluoride PET, and serial echocardiography during 2 years of follow-up. RESULTS: All ex vivo, degenerate bioprosthetic valves displayed 18F-fluoride PET uptake that colocalized with tissue degeneration on histology. In 71 patients without known bioprosthesis dysfunction, 14 had abnormal leaflet pathology on CT, and 24 demonstrated 18F-fluoride PET uptake (target-to-background ratio 1.55 [interquartile range (IQR): 1.44 to 1.88]). Patients with increased 18F-fluoride uptake exhibited more rapid deterioration in valve function compared with those without (annualized change in peak transvalvular velocity 0.30 [IQR: 0.13 to 0.61] vs. 0.01 [IQR: -0.05 to 0.16] ms-1/year; p < 0.001). Indeed 18F-fluoride uptake correlated with deterioration in all the conventional echocardiographic measures of valve function assessed (e.g., change in peak velocity, r = 0.72; p < 0.001). Each of the 10 patients who developed new overt bioprosthesis dysfunction during follow-up had evidence of 18F-fluoride uptake at baseline (target-to-background ratio 1.89 [IQR: 1.46 to 2.59]). On multivariable analysis, 18F-fluoride uptake was the only independent predictor of future bioprosthetic dysfunction. CONCLUSIONS: 18F-fluoride PET-CT identifies subclinical bioprosthetic valve degeneration, providing powerful prediction of subsequent valvular dysfunction and highlighting patients at risk of valve failure. This technique holds major promise in the diagnosis of valvular degeneration and the surveillance of patients with bioprosthetic valves. (18F-Fluoride Assessment of Aortic Bioprosthesis Durability and Outcome [18F-FAABULOUS]; NCT02304276).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Cartlidge TRG, Doris MK, Sellers SL, et al. Detection and Prediction of Bioprosthetic Aortic Valve Degeneration. J Am Coll Cardiol. 2019. PMID: 30871693. doi:10.1016/j.jacc.2018.12.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。